Serina Therapeutics Announces Board and Executive Changes
Ticker: SER · Form: 8-K · Filed: Jan 15, 2025 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Jan 15, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
TL;DR
Serina Therapeutics shakes up its board and exec pay structure.
AI Summary
Serina Therapeutics, Inc. announced on January 14, 2025, changes related to its board of directors and executive compensation. The filing details the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for key executives.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect the company's strategic direction and operational stability.
Key Numbers
- 1-38519 — Commission File Number (SEC File Number for Serina Therapeutics, Inc.)
- 82-1436829 — IRS Employer Identification No. (Tax identification number for Serina Therapeutics, Inc.)
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Registrant
- January 14, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Huntsville, Alabama (location) — Principal executive offices
- AgeX Therapeutics, Inc. (company) — Former company name
FAQ
What specific roles were affected by the departure of officers and directors?
The filing indicates the departure of 'certain officers' and 'certain directors' but does not specify the exact roles in this summary section.
Who are the newly elected directors?
The filing mentions the election of directors but does not name the individuals in the provided text.
What are the details of the compensatory arrangements for certain officers?
The filing notes changes to compensatory arrangements but does not provide specific details on the nature or value of these arrangements.
When was the company formerly known as AgeX Therapeutics, Inc.?
The company's name was changed from AgeX Therapeutics, Inc. on June 6, 2017.
What is the primary business of Serina Therapeutics, Inc.?
Serina Therapeutics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Filing Stats: 752 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2025-01-14 17:37:22
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share SE R NYSE American Indicate
Filing Documents
- ser-20250114.htm (8-K) — 28KB
- a991-pressreleasexappointm.htm (EX-99.1) — 11KB
- 0001708599-25-000005.txt ( ) — 249KB
- ser-20250114.xsd (EX-101.SCH) — 2KB
- ser-20250114_lab.xml (EX-101.LAB) — 53KB
- ser-20250114_pre.xml (EX-101.PRE) — 31KB
- ser-20250114_htm.xml (XML) — 3KB
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release announcing the appointment of Kare n J . Wilson to the Company's Board of Directors 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: January 14, 2025 By: /s/ Steve Ledger Chief Executive Officer